The higher initial dose and accelerated titration regimen of ropeginterferon as a treatment option for certain patients with polycythaemia vera

Documenti analoghi

• Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b
  di: Shanshan Suo, et al.
  Pubblicazione: (2024)
• The dosage of ropeginterferon in polycythaemia vera: Balancing efficacy, safety and pharmacoeconomics across risk categories
  di: Tiziano Barbui, et al.
  Pubblicazione: (2025)
• Melanonychia in polycythaemia vera patient treated with hydroxycarbamide
  di: Marko Lucijanic, et al.
  Pubblicazione: (2025)
• Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy
  di: Tiziano Barbui, et al.
  Pubblicazione: (2024)
• Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma
  di: M. R. Seefat, et al.
  Pubblicazione: (2025)